埃克替尼一线及加量治疗表皮生长因子受体突变晚期肺腺癌患者1例  

Treatment with high-dose icotinib in a lung adenocarcinoma patient with epidermal growth factor receptor mutation

作　　者：李艳莹[1] 余敏[1] 陈芙蓉[1] 黄媚娟[1] 

机构地区：[1]四川大学华西医院胸部肿瘤科,成都610041

出　　处：《中国新药杂志》2013年第11期1307-1310,共4页Chinese Journal of New Drugs

摘　　要：对于表皮生长因子受体(epidermal growth factor receptor,EGFR)突变的晚期非小细胞肺癌(non-small cell lung cancer,NSCLC),表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptortyrosine kinase inhibitor,EGFR-TKI)已经成为一线治疗的优选方案。我院采用我国自主研发的小分子靶向药物埃克替尼125 mg,tid口服治疗了1例EGFR突变的晚期肺腺癌患者,10 d后患者症状明显缓解,1个月后双肺弥漫结节缩小、消失,疗效评价为稳定(stable disease,SD)。继续服药,每3个月定期复查,双肺结节继续缩小。用药11个月后出现肺部病灶缓慢长大,继续服药1个月后复查见肺部病灶仍继续缓慢长大,将埃克替尼加量,125 mg,tid及250 mg,tid交替口服。加量45 d后复查病灶再次得到控制。Epidermal growth factor receptor tyrosine kinase inhibitors have been a preferred selection for NSCLC patients with EGFR mutation as the first line therapy. Icotinib is a small molecular targeted drug which was independently developed in our country. An advanced lung adenocarcinoma patient with EGFR mutation took icotinib at the recommended dose of 125 mg three times per day. The patient＇s symptoms obviously alleviated 10 days after treatment, and the diffuse micronodular on both lungs began to disappear or diminish 1 month later. The patient continued to take icotinib and was estimated every three months. The tumors in both lungs began to progress slowly after 11 months from the start of the therapy. Then the patient continued to take icotinib for one month and was evaluated again. The lung tumors progressed slowly yet. We increased the dose of icotinib as alternate uses of 125 mg three times a day and 250 mg three times a day. Tumor evaluation was SD at 45 days after dose was increased.

关 键 词：埃克替尼 肺癌 表皮生长因子受体 晚期 酪氨酸激酶抑制剂 

分 类 号：R979.1[医药卫生—药品]